Krystal Biotech 향후 성장
Future 기준 점검 5/6
Krystal Biotech (는) 각각 연간 40.6% 및 34.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 37.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16.9% 로 예상됩니다.
핵심 정보
40.6%
이익 성장률
37.14%
EPS 성장률
| Biotechs 이익 성장 | 29.1% |
| 매출 성장률 | 34.7% |
| 향후 자기자본이익률 | 16.87% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 11 Sep 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Sep 03
KRYS: Future Ophthalmology And CF Readouts Will Drive Long Term Upside
Analysts have raised their central price target for Krystal Biotech stock from $371 to $474 as they factor in higher projected revenue growth, a higher future P/E multiple, and broader potential for the company's HSV-1 based gene therapy platform in dermatology, ocular, and lung indications. Analyst Commentary on Krystal Biotech Recent Street research on Krystal Biotech points to a cluster of higher price targets and supportive commentary around both the commercial rollout of Vyjuvek and the breadth of the HSV-1 gene therapy platform.
내러티브 업데이트 • Aug 19
KRYS: Future Returns Will Hinge On 2026 Ophthalmology And CF Readouts
Analysts lifted their blended fair value estimate for Krystal Biotech stock from about $362 to $385, citing higher assumed revenue growth, improved profit margin assumptions, and a lower future P/E multiple, supported by recent price target updates that emphasize the potential of Vyjuvek and the broader pipeline in eye and lung indications. Analyst Commentary Recent Street commentary on Krystal Biotech highlights a mix of optimism around Vyjuvek and the broader pipeline, alongside some caution on execution and upcoming data.
내러티브 업데이트 • Aug 05
KRYS: Ophthalmology Readouts Will Test Overextended Pipeline Expectations
Analysts have increased their consolidated fair value estimate for Krystal Biotech stock from $241 to $284, reflecting updated price targets that weigh mixed Q2 feedback against ongoing expectations for product demand, pipeline progress, and new asset contributions. Analyst Commentary Recent Street research on Krystal Biotech shows a wide range of fair value views, with several firms setting targets in the high US$300s to mid US$400s and maintaining positive ratings even after what some describe as a mixed Q2 report.Seeking Alpha • Jul 29
Krystal Biotech: Profitable, Self-Funding, And Loaded With Optionality
Summary Krystal Biotech remains a Buy as VYJUVEK drives profitability and its HSV-1 platform underpins a robust pipeline. Q1 results highlight operating leverage: $116.4M VYJUVEK revenue, $56M net income, and self-funded R&D with a $1B cash position. Upcoming catalysts include registrational data for KB803 and KB801, with KB801 positioned as a potential blockbuster in rare ophthalmology. KRYS trades at a premium valuation, justified by pipeline optionality and near-term catalysts, though risks include clinical failures and reliance on VYJUVEK. Read the full article on Seeking Alpha내러티브 업데이트 • Jul 22
KRYS: Future Returns Will Weigh UK Approval Against 2026 Ophthalmology And CF Data
Krystal Biotech's analyst price target has been reset higher from $349.78 to $361.67. Analysts point to updated assumptions that include slightly lower discount rates, modestly adjusted growth and margin inputs, and increased confidence in future product contributions reflected in higher outer year revenue expectations and P/E multiples.내러티브 업데이트 • Jul 07
KRYS: Future Returns Will Balance UK Approval With 2026 Pipeline Execution Risks
Krystal Biotech's implied analyst price target in this framework has shifted higher by about $27 to $349.78, as analysts factor in expected value from late stage dermatology data, early cystic fibrosis readouts and the first inclusion of the inhaled KB707 program. Analyst Commentary Recent Street research on Krystal Biotech points to a wide range of views on how the current pipeline and data catalysts may translate into long term value.내러티브 업데이트 • Jun 23
KRYS: Ophthalmology Readouts And KB707 Lung Data Will Test Pipeline Expectations
The analyst price target for Krystal Biotech has shifted, with updated models incorporating revised discount rate and growth assumptions, along with expectations for pipeline catalysts that include TD Cowen's move to $403, H.C. Wainwright's to $361, and fresh contributions from new asset KB707 and other late stage ophthalmology programs. Analyst Commentary on Krystal Biotech Recent research on Krystal Biotech highlights a mix of optimism around its pipeline and caution around execution, timelines, and how much future opportunity is already reflected in the stock.내러티브 업데이트 • Jun 09
KRYS: Future Returns Will Reflect UK Approval And Mixed Execution Debate
Krystal Biotech's analyst price target has shifted modestly by a few dollars as analysts factor in recent mixed revisions, including small upward moves from several firms and a larger $27 adjustment from another, while keeping core valuation inputs such as fair value, discount rate, revenue growth, profit margin, and future P/E essentially unchanged. Analyst Commentary Recent research updates around Krystal Biotech reflect both optimism and caution, with several firms adjusting price targets in different directions while keeping core assumptions broadly intact.내러티브 업데이트 • May 26
KRYS: Future Returns Will Reflect UK Approval And Debated Execution Risks
Krystal Biotech's updated fair value estimate has shifted from $315 to about $322.78 as analysts adjust models around revenue growth, margins, and P/E assumptions. This reflects the mixed but generally supportive reset in Street price targets following recent research updates from multiple firms.분석 기사 • May 13
There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings
Krystal Biotech, Inc. ( NASDAQ:KRYS ) just reported some strong earnings, and the market reacted accordingly with a...내러티브 업데이트 • May 01
KRYS: Future Returns Will Reflect Lung Cancer RMAT Milestone And Oncology Pipeline Execution
Analysts have raised their average price target on Krystal Biotech from $291 to $315. This reflects updated models that incorporate Vyjuvek sales assumptions, FY25 financials, and progress across multiple registrational programs following the latest Q4 report and management meetings.내러티브 업데이트 • Apr 17
KRYS: Oncology Immunotherapy RMAT And Respiratory Programs Will Test Rare Disease Optimism
Analysts have lifted their average price target on Krystal Biotech by $7, reflecting updates to models around Vyjuvek sales expectations, FY25 financials, and the advancing pipeline, while incorporating a slightly higher discount rate and modestly revised revenue growth, profit margin, and P/E assumptions. Analyst Commentary Recent Street research on Krystal Biotech shows a wide spread of opinion, with several firms lifting price targets following the latest quarterly report and updated models for Vyjuvek and the broader pipeline.내러티브 업데이트 • Apr 01
KRYS: Future CF And Ophthalmology Readouts Will Drive Long Term Upside
Krystal Biotech's analyst price target is maintained at $371, with analysts pointing to refined revenue growth and margin assumptions, along with Q4-driven updates to Vyjuvek forecasts and the broader pipeline, as key supports for the current valuation framework. Analyst Commentary Bullish analysts have been steadily revisiting their models on Krystal Biotech following recent updates on Vyjuvek, the broader pipeline, and Q4 results.내러티브 업데이트 • Mar 18
KRYS: Future CF And Ophthalmology Readouts Will Shape Long Term Upside
Narrative Update on Krystal Biotech The analyst fair value estimate for Krystal Biotech has shifted from $336 to $371, with the change largely tied to higher Vyjuvek sales assumptions, updated FY25 forecasts, and continued progress across multiple registrational and pivotal pipeline programs cited in recent research updates. Analyst Commentary Recent research updates on Krystal Biotech point to a cluster of upward price target revisions, with bullish analysts citing refreshed financial models, Vyjuvek launch assumptions, and advancing clinical programs across multiple indications as key inputs.내러티브 업데이트 • Mar 04
KRYS: Rising Oncology And Respiratory Pipeline Expectations May Test Rare Disease Optimism
The analyst price target for Krystal Biotech has been raised from $202 to $241, with analysts pointing to updated models that reflect higher Vyjuvek sales assumptions, refined FY25 financials, and advancing registrational trials across multiple programs. Analyst Commentary Recent Street research on Krystal Biotech highlights a series of upward price target revisions clustered around the latest quarterly update, Vyjuvek launch assumptions, and progress across the pipeline.내러티브 업데이트 • Feb 18
KRYS: Future Returns Will Reflect Vyjuvek Penetration And CF And Oncology Pipeline Execution
Narrative Update: Krystal Biotech Analyst Price Target Shift The analyst price target for Krystal Biotech has been revised higher from $273.60 to $291.22, with analysts pointing to recent model updates that reflect Vyjuvek demand trends, advancing ophthalmology programs, and early data from the broader pipeline. Analyst Commentary Recent Street research on Krystal Biotech points to a cluster of upward price target revisions, with most commentary tying those changes to product traction for Vyjuvek, the maturing ophthalmology pipeline, and early data in cystic fibrosis and other programs.내러티브 업데이트 • Feb 04
KRYS: Future CF Data Readouts May Redefine Long Term Upside Potential
Analysts have increased their price target on Krystal Biotech from $252 to $336, citing updated models that factor in revised assumptions for revenue growth, profit margins, and future P/E multiples following recent clinical data and pipeline updates. Analyst Commentary Recent Street research on Krystal Biotech has centered on a series of higher price targets, with bullish analysts revisiting their models after clinical updates and product pipeline progress.내러티브 업데이트 • Jan 21
KRYS: Future Returns Will Reflect 96% Margins And Early CF Pipeline Progress
We are raising our analyst price target on Krystal Biotech from $223 to $273.60. This reflects updated models that incorporate recent analyst work on Vyjuvek, early KB407 cystic fibrosis data, and revised assumptions for revenue growth, profit margin, and future P/E multiples.내러티브 업데이트 • Jan 07
KRYS: Elevated Expectations For Rare Disease Portfolio May Prove Unsustainable
Analysts have lifted their Krystal Biotech fair value estimate from US$176 to US$202, citing higher price targets from recent research, improving access to capital for biotech, and support from Vyjuvek revenue trends and gross margin performance. Analyst Commentary Recent Street research has generally framed Krystal Biotech within a more constructive backdrop for U.S. biotech, pointing to supportive data readouts, active dealmaking by larger peers, and what some describe as better access to capital.내러티브 업데이트 • Dec 15
KRYS: Future Returns Will Reflect 96% Margins And Expanding International Uptake
Analysts have nudged their price target on Krystal Biotech higher to about $220, reflecting stronger than expected Vyjuvek revenue, early traction from the Germany launch, and exceptionally high gross margins that support the company’s long term profitability outlook. Analyst Commentary Bullish analysts point to the latest quarter as evidence that Krystal Biotech is executing ahead of expectations, with Vyjuvek demand and geographic expansion translating into faster top line growth and stronger earnings power than previously modeled.내러티브 업데이트 • Dec 01
KRYS: Future Results Will Reflect Margin Strength and International Launch Performance
Analysts have raised their price target for Krystal Biotech to $220, up from $216. They cite stronger-than-expected Vyjuvek revenue, international sales growth, and robust gross margins as key drivers behind the increased valuation.내러티브 업데이트 • Nov 17
KRYS: Future Momentum Will Depend on Gross Margin Strength and Pipeline Progress
Analysts have increased Krystal Biotech’s price target from $212.50 to $223.00. They cite stronger-than-expected Vyjuvek revenue, expansion in Germany, and improved profit margins as key factors supporting the higher valuation.분석 기사 • Nov 10
Investors Shouldn't Be Too Comfortable With Krystal Biotech's (NASDAQ:KRYS) Earnings
Krystal Biotech, Inc.'s ( NASDAQ:KRYS ) robust earnings report didn't manage to move the market for its stock. Our...내러티브 업데이트 • Nov 01
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
Krystal Biotech's average analyst price target has been revised downward, with a reduction of up to $10 per share. Analysts cite updated product prioritizations, mixed quarterly results, and cautious near-term revenue forecasts.내러티브 업데이트 • Oct 18
Global Expansion And Clinical Readouts Will Unlock New Markets
The analyst consensus price target for Krystal Biotech has increased from $205.20 to $212.50. This change reflects updated evaluations as analysts factor in new product development priorities and ongoing commercial performance.분석 기사 • Oct 09
Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher
The Krystal Biotech, Inc. ( NASDAQ:KRYS ) share price has done very well over the last month, posting an excellent gain...Seeking Alpha • Feb 21
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Summary Krystal Biotech's VYJUVEK shows strong growth, with 2025 sales expected to exceed $1B, bolstered by launches in the EU and Japan. Q4 earnings beat EPS expectations but slightly missed revenue forecasts; however, management's 2025 outlook coming catalysts drove a strong rally in shares. Key 2025 catalysts include VYJUVEK's EU and Japan launches, Phase 3 ocular DEB results, and progress in CF and lung gene therapy. KRYS stock remains a STRONG BUY with a $225/share 12-month target, driven by impressive growth and new market opportunities. Read the full article on Seeking AlphaSeeking Alpha • Oct 14
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Summary The company anticipates significant Q4 2024 data releases for KB707 in solid tumors and KB408 in AATD lung disease, potentially boosting shareholder value. Jeune Therapeutics, a subsidiary, shows promise in aesthetics with positive phase 1 data, changing the treatment paradigm in the aesthetics market space. VYJUVEK, approved for DEB, saw a 55.3% revenue increase in Q2 2024, with potential European expansion pending MAA approval. Financially stable with $628.9M cash, but may need additional funding within 12 months; has a $150M ATM agreement with Cowen & Co. LLC. in place if necessary. Read the full article on Seeking Alpha
새로운 내러티브 • Aug 29
Expanding Global Reach With VYJUVEK Set To Skyrocket Revenue And Sharpen Market Edge
International expansion and upcoming product launches indicate significant potential for revenue growth and market diversification.Seeking Alpha • Jul 31
Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Summary Krystal Biotech's Q1 2024 revenue increased to $45.25 million but fell short of analyst expectations of $47.37 million. Analysts expect Q2 earnings to be $65.49 million. Vyjuvek's patient adherence rate dropped slightly to 91% in Q1 from 96% in the previous quarter. Krystal's pipeline, beyond dermatological and aesthetic pursuits, is pretty speculative and pursuing highly contested indications. I recommend a rating downgrade "hold" for Krystal due to its high valuation. Read the full article on Seeking Alpha이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 957 | 526 | 697 | 482 | 7 |
| 12/31/2027 | 655 | 307 | 334 | 352 | 9 |
| 12/31/2026 | 513 | 237 | 342 | 320 | 8 |
| 6/30/2026 | 440 | 241 | 258 | 272 | N/A |
| 3/31/2026 | 417 | 225 | 237 | 250 | N/A |
| 12/31/2025 | 389 | 205 | 189 | 201 | N/A |
| 9/30/2025 | 373 | 199 | 166 | 176 | N/A |
| 6/30/2025 | 359 | 147 | 185 | 195 | N/A |
| 3/31/2025 | 333 | 124 | 129 | 139 | N/A |
| 12/31/2024 | 291 | 89 | 119 | 123 | N/A |
| 9/30/2024 | 242 | 52 | 58 | 63 | N/A |
| 6/30/2024 | 166 | 106 | -23 | -17 | N/A |
| 3/31/2024 | 96 | 57 | -54 | -47 | N/A |
| 12/31/2023 | 51 | 11 | -101 | -89 | N/A |
| 9/30/2023 | 9 | -30 | -119 | -104 | N/A |
| 6/30/2023 | N/A | -140 | -130 | -102 | N/A |
| 3/31/2023 | N/A | -135 | -152 | -111 | N/A |
| 12/31/2022 | N/A | -140 | -154 | -101 | N/A |
| 9/30/2022 | N/A | -130 | -188 | -99 | N/A |
| 6/30/2022 | N/A | -115 | -182 | -87 | N/A |
| 3/31/2022 | N/A | -104 | -137 | -54 | N/A |
| 12/31/2021 | N/A | -70 | -116 | -48 | N/A |
| 9/30/2021 | N/A | -58 | -70 | -35 | N/A |
| 6/30/2021 | N/A | -52 | -52 | -35 | N/A |
| 3/31/2021 | N/A | -43 | -45 | -30 | N/A |
| 12/31/2020 | N/A | -32 | -41 | -26 | N/A |
| 9/30/2020 | N/A | -27 | -35 | -25 | N/A |
| 6/30/2020 | N/A | -22 | -29 | -23 | N/A |
| 3/31/2020 | N/A | -20 | N/A | -22 | N/A |
| 12/31/2019 | N/A | -19 | N/A | -19 | N/A |
| 9/30/2019 | N/A | -17 | N/A | -15 | N/A |
| 6/30/2019 | N/A | -16 | N/A | -13 | N/A |
| 3/31/2019 | N/A | -13 | N/A | -10 | N/A |
| 12/31/2018 | N/A | -11 | N/A | -9 | N/A |
| 9/30/2018 | N/A | -9 | N/A | -8 | N/A |
| 6/30/2018 | N/A | -11 | N/A | -7 | N/A |
| 3/31/2018 | N/A | -10 | N/A | -6 | N/A |
| 12/31/2017 | N/A | -8 | N/A | -4 | N/A |
| 9/30/2017 | N/A | -7 | N/A | -3 | N/A |
| 6/30/2017 | N/A | -2 | N/A | -2 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: KRYS 의 연간 예상 수익 증가율(40.6%)이 saving rate(3.7%)보다 높습니다.
수익 vs 시장: KRYS 의 연간 수익(40.6%)이 US 시장(17.4%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 수익: KRYS 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.
수익 대 시장: KRYS 의 수익(연간 34.7%)이 US 시장(연간 13.5%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: KRYS 의 수익(연간 34.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: KRYS의 자본 수익률은 3년 후 16.9%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/18 13:55 |
| 종가 | 2026/09/18 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Krystal Biotech, Inc.는 20명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Caroline Palomeque | Berenberg |
| Alec Stranahan | BofA Global Research |
| Justin Zelin | B. Riley Securities, Inc. |